US pharmaceutical companies are openly considering delaying, or even withholding, new medicines from Europe in a high‑stakes fight over price controls — a move that could reshape how and where patients get access to new drugs, and where the industry chooses to invest.
US pharma raises the stakes
Executives from companies including Pfizer and Bristol Myers Squibb have told investors and policymakers that they are “actively reassessing” launch plans for upcoming therapies in major European markets, according to people who attended the JPMorgan healthcare conference in San Francisco this week.
One senior attendee described the mood as “combative”, as executives weighed whether Europe’s tough stance on prices still justifies early access to cutting‑edge medicines.
“When we do the math, shall we reduce the US price to France’s level or stop supplying France? We will stop supplying France,” Pfizer chief executive Albert Bourla told reporters on the sidelines of the conference, according to people familiar with the closed‑door discussion.
Trump’s pricing squeeze flips the script
The showdown follows a series of agreements struck last year between President Donald Trump and more than a dozen multinational drugmakers. In exchange for avoiding steep import tariffs, companies agreed to cut some US prices and to tie Medicaid reimbursement more closely to the lowest prices paid in other wealthy countries.
On Wall Street, those deals were initially seen as a tolerable compromise. The concessions were limited to parts of company portfolios, and the removal of tariff risk was widely welcomed.
The details are now coming back to bite. By anchoring US prices to international benchmarks, Washington has effectively imported Europe’s tight price controls into the American market, turning low prices in Paris or Berlin into a direct drag on US margins.
For executives, that linkage has upended the usual political narrative.
“Europe used to be the cheap launch market you tolerated,” said a New York‑based healthcare fund manager. “Now every lowball deal in Paris or Berlin punches a hole in your US economics.”
Europe pushes back on ‘bullying’
European health authorities insist they already pay a fair price for new drugs and reject the idea that they are free‑riding on US innovation.
Germany’s largest public health insurer, TK, has argued that companies benefit from strong volumes and predictable reimbursement in Europe, even if headline prices are lower than in the US.
In France, a senior health ministry official, speaking on condition of anonymity, said the latest warnings from US drugmakers amount to “economic blackmail”.
“We cannot allow patient access to be weaponised in a transatlantic trade dispute,” the official said. “If a company walks away, we will look to other suppliers, including generics and biosimilars.”
Patient groups are worried, but not united. Some say a hard line on prices risks leaving cancer and rare‑disease patients waiting years for treatments already available in the US. Others argue that governments should stand firm.
One advocacy leader in Spain described the companies’ stance as “hostage taking by Big Pharma”.
Launch calculus: delay Europe to protect US profits
Behind the rhetoric sits a blunt piece of arithmetic. If a new drug is launched at a steep discount in Italy or Spain, that lower price can feed back into the US reference basket under the Trump‑era formulas, pulling down American reimbursement for Medicaid and potentially other programmes if similar models spread.
For drugmakers, that creates a powerful incentive to think again about how quickly to launch in lower‑priced markets.
“Companies are running the numbers and finding that a fast launch in Europe could destroy value in their largest market,” said Gareth Powell, head of healthcare at London‑based Polar Capital. “In that context, holding back for a few years starts to look rational, if brutal.”
Several executives at the JPMorgan meeting acknowledged privately that they are sketching out scenarios in which new medicines launch first in the US, then in high‑price Asian markets, while roll‑outs in parts of the EU are delayed, narrowed or both.
“The system will force us not to be able to accept the lower prices,” Bourla said, warning that some countries “will stay without new medicines” unless they improve their offers.
Billions in revenue — and reputations — on the line
Europe typically accounts for roughly 20 to 30 per cent of global sales for big US drugmakers, depending on their product mix. Pulling back in any meaningful way would put billions of dollars in revenue at risk over time.
It would also test investors’ patience. So far, shares in major pharma groups have largely shrugged off the war of words, with many investors assuming that both sides will compromise before access is seriously curtailed.
Analysts argue that in most cases companies could accept somewhat lower prices rather than abandon entire national markets altogether.
Still, some portfolio managers warn that markets may be underestimating the political risk.
“If this spirals, you could see longer launch lags in Europe, messy headlines about patients denied drugs, and pressure on ESG‑minded investors to respond,” said Linden Thomson, senior portfolio manager at Candriam. “That’s not a scenario anyone is modelling yet.”
Brussels weighs options as industry hardens its tone
The dispute comes as the EU finalises a broad overhaul of its pharmaceutical rules, including changes to data and market exclusivity that companies say will further chip away at returns on European research and development.
In a recent letter to the Financial Times, the chief executives of Novartis and Sanofi warned that rigid price controls and shrinking incentives are already pushing investment and manufacturing toward the US and Asia. They urged Brussels to “fairly reward innovation” or risk a lasting loss of competitiveness.
EU officials counter that public health budgets are being stretched by ageing populations and the arrival of ultra‑expensive cell and gene therapies. One senior Brussels policymaker said there was “limited appetite” among member states to “pay US‑style prices simply because Washington has chosen this path”.
For now, the two sides appear to be talking past each other:
- Industry leaders argue Europe must pay more if it wants to remain a serious centre for pharmaceutical innovation.
- European governments insist that innovation must adapt to what taxpayers can realistically afford.
The result is a standoff in which patients and investors are left guessing how far drugmakers are really willing to go.
If US companies follow through and start slow‑walking launches across the Atlantic, the current brinkmanship will move from conference podiums into hospital formularies — and, soon after, into quarterly earnings reports.
The open question is whether anyone, on either side of the ocean, is truly prepared for that outcome.
